Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Payables (2016 - 2025)

Ultragenyx Pharmaceutical has reported Payables over the past 11 years, most recently at $31.0 million for Q4 2025.

  • Quarterly Payables fell 20.51% to $31.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 20.51% year-over-year, with the annual reading at $31.0 million for FY2025, 20.51% down from the prior year.
  • Payables was $31.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $40.6 million in the prior quarter.
  • Over five years, Payables peaked at $59.8 million in Q2 2024 and troughed at $15.6 million in Q3 2021.
  • The 5-year median for Payables is $35.1 million (2024), against an average of $35.0 million.
  • Year-over-year, Payables surged 152.5% in 2022 and then crashed 42.75% in 2025.
  • A 5-year view of Payables shows it stood at $17.1 million in 2021, then soared by 152.5% to $43.3 million in 2022, then fell by 2.68% to $42.1 million in 2023, then fell by 7.39% to $39.0 million in 2024, then fell by 20.51% to $31.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Payables are $31.0 million (Q4 2025), $40.6 million (Q3 2025), and $34.2 million (Q2 2025).